Abstract
Toxicity and efficacy concerns are the main drivers of the high attrition rate in the pharmaceutical pipelines. Many factors contribute to these concerns, but an important issue is the uncertainty in the extrapolation from experimental models to humans. Complex in vitro models (CIVMs) could provide a key to resolving some of this uncertainty by increasing the translational potential between the laboratory and the clinic. A CIVM subtype, microphysiological systems (MPS), are being developed to better mimic human physiology. There are two main types of MPS, microfluidic systems and organotypic constructs, that are applicable to drug development, toxicity testing, disease modeling, personalized medicine, developmental biology, and animal model replacement. These more physiologically complex models combine various organ tissues and both organotypic and microfluidic technologies. They are used mainly in drug absorption, metabolism, and toxicity studies and the pharmaceutical industry has been using them for internal validation of their pipelines. Although not yet fully ready for regulatory purposes, the regulatory bodies are supportive of this technology as a possible means to replace animals in toxicity testing. Moreover, the technology has potential to improve many aspects of drug discovery and development.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Toxicological Risk Assessment and Multi-System Health Impacts From Exposure
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
